Supplementary Tables S1-S4 and Supplementary Figures S1-S12 from Digitalis-like Compounds Facilitate Non-Medullary Thyroid Cancer Redifferentiation through Intracellular Ca²⁺, FOS, and Autophagy-Dependent Pathways

Table S1. Overview of selected autophagy activating compounds, their structure, chemical and pharmacological classification and the supplier; Table S2. Significantly upregulated genes in all cell lines at all time points (fold change log2 {greater than or equal to} 1); Table S3. Significantly downregulated genes in all cell lines at all time points (fold change log2 {less than or equal to} -1); Table S4. Physicochemical properties of digitalis-like compounds predicted by ChemBioOf�ce software; Figure S1: Visualization of whole transcriptome data of BC-PAP treated with 50 µM proscillaridin A for 24, 48 or 72 hours, comprising principal component analysis and Venn diagrams of overlapping genes, either up- or downregulated, between 24, 48 and 72 hours time points; Figure S2: Visualization of whole transcriptome data of FTC133 treated with 50 µM digoxin for 24, 48 or 72 hours, comprising principal component analysis and Venn diagrams of overlapping genes, either up- or downregulated, between 24, 48 and 72 hours time points; Figure S3: Visualization of whole transcriptome data of FTC133 treated with 50 µM digoxigenin for 24, 48 or 72 hours, comprising principal component analysis and Venn diagrams of overlapping genes, either up- or downregulated, between 24, 48 and 72 hours time points; Figure S4: Visualization of whole transcriptome data of FTC133 treated with 50 µM proscillaridin A for 24, 48 or 72 hours, comprising principal component analysis and Venn diagrams of overlapping genes, either up- or downregulated, between 24, 48 and 72 hours time points; Figure S5: Visualization of whole transcriptome data of FTC133 treated with 50 µM strophantin K for 24, 48 or 72 hours, comprising principal component analysis and Venn diagrams of overlapping genes, either up- or downregulated, between 24, 48 and 72 hours time points; Figure S6: Visualization of whole transcriptome data of TPC-1 treated with lanatoside C for 24, 48 or 72 hours, comprising principal component analysis and Venn diagrams of overlapping genes, either up- or downregulated, between 24, 48 and 72 hours time points; Figure S7: STRING protein interaction networks of significantly up- or downregulated genes by digitalis-like compounds in all three cell lines and at all three time points; Figure S8: Bonferroni corrected P-value enrichment scores of significantly upregulated pathways by digitalis-like compounds combined for all three cell lines and for all three time points. P-values are generated by using the Gene Ontology (GO) platform category Biological Processes; Figure S9: Expression of JUN after treatment for 48 and 72 hours of BC-PAP, FTC133 and TPC-1 with the indicated digitalis-like compounds. Data are obtained from three independent experiments. Data are means {plus minus} SD. Square boxes represent statistical output of Spearman's rho tests for degree of correlation between expression of JUN with hNIS expression at 48 and 72 hours time points; Figure S10: Gene expression of thyroid transcription factors TTF1, TTF2 and PAX8 in BC-PAP, FTC133 or TPC-1 after treatment with the indicated digitalis-like compounds for 48 or 72 hours. Data are obtained from three independent experiments. Data are means {plus minus} SD; Figure S11: Heatmaps depicting gene expression of ABC transporters and organic anion transporters in untreated and digitalis-like compound treated BC-PAP, FTC133 and TPC-1 (N=6); Figure S12: Full unedited Western blot pictures, cropped pictures are depicted in Figure 1B.